Enliven Therapeutics (ELVN) PT Raised to $45 at Mizuho, 'Still an under-rated asset in the CML space'
Tweet Send to a Friend
Mizuho analyst Salim Syed raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $45.00 (from $41.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
